Graham Robertson

Graham Robertson

Auto-generated profile, based on publicly available information

Graham Robertson

Centre for Microsystems and Photonics, Electronic and Electrical Engineering, University of Strathclyde, Glasgow, G1 1XW, UK

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2012 in Aging
Verified
Journal Article
Open access
ASAngie M. Y. Shum
Angie M. Y. Shum
TMTheodore Mahendradatta
Theodore Mahendradatta
RTRyland J. Taylor
Ryland J. Taylor
APArran B. Painter
Arran B. Painter
MMMelissa M. Moore
Melissa M. Moore
PPPatsie Polly
Patsie Polly
Cancer cachexia is a highly debilitating paraneoplastic disease observed in more than 50% of patients with advanced cancers and directly contributes to 20% of cancer deaths. Loss of skeletal muscle is a defining characteristic of patients with cancer cachexia and is associated with poor survival. The present study reveals the involvement of a myogenic transcription factor Myocyte Enhancer Factor (MEF) 2C in cancer-induced skeletal muscle wasting. Increased skeletal muscle mRNA expression of Suppressor of Cytokine Signaling (Socs) 3 and the IL-6 receptor indicative of active IL-6 signaling was seen in skeletal muscle of mice bearing the Colon 26 (C26) carcinoma. Loss of skeletal muscle structural integrity and distorted mitochondria were also observed using electron microscopy. Gene and protein expression of MEF2C was significantly downregulated in skeletal muscle from C26-bearing mice. MEF2C gene targets myozenin and myoglobin as well as myokinase were also altered during cachexia, suggesting dysregulated oxygen transport capacity and ATP regeneration in addition to distorted structural integrity. In addition, reduced expression of calcineurin was observed which suggested a potential pathway of MEF2C dysregulation. Together, these effects may limit sarcomeric contractile ability and also predispose skeletal muscle to structural instability; associated with muscle wasting and fatigue in cachexia.

6 May 2014 in Integrative Biology
Verified
Journal Article
Open access
PDF file
GRGraham Robertson
Graham Robertson
TBTrevor Bushell
Trevor Bushell
MZMichele Zagnoni
Michele Zagnoni
A novel methodology is presented for probing the functional synaptic connectivity between mixed primary hippocampal co-cultures.

21 September 2016 in Scientific Reports
Verified
Journal Article
Open access
ASAndrew Samson
Andrew Samson
GRGraham Robertson
Graham Robertson
MZMichele Zagnoni
Michele Zagnoni
CCChristopher N. Connolly
Christopher N. Connolly
Acute secondary neuronal cell death, as seen in neurodegenerative disease, cerebral ischemia (stroke) and traumatic brain injury (TBI), drives spreading neurotoxicity into surrounding, undamaged, brain areas. This spreading toxicity occurs via two mechanisms, synaptic toxicity through hyperactivity, and excitotoxicity following the accumulation of extracellular glutamate. To date, there are no fast-acting therapeutic tools capable of terminating secondary spreading toxicity within a time frame relevant to the emergency treatment of stroke or TBI patients. Here, using hippocampal neurons (DIV 15–20) cultured in microfluidic devices in order to deliver a localized excitotoxic insult, we replicate secondary spreading toxicity and demonstrate that this process is driven by GluN2B receptors. In addition to the modeling of spreading toxicity, this approach has uncovered a previously unknown, fast acting, GluN2A-dependent neuroprotective signaling mechanism. This mechanism utilizes the innate capacity of surrounding neuronal networks to provide protection against both forms of spreading neuronal toxicity, synaptic hyperactivity and direct glutamate excitotoxicity. Importantly, network neuroprotection against spreading toxicity can be effectively stimulated after an excitotoxic insult has been delivered, and may identify a new therapeutic window to limit brain damage.

2 March 2018 in Neuropharmacology
Verified
Journal Article
Closed access
LRLouise Ritchie
Louise Ritchie
RTRothwelle J. Tate
Rothwelle J. Tate
LCLuke H. Chamberlain
Luke H. Chamberlain
GRGraham Robertson
Graham Robertson
MZMichele Zagnoni
Michele Zagnoni
TBTrevor Bushell
Trevor Bushell

16 November 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CMChristopher MacKerron
Christopher MacKerron
GRGraham Robertson
Graham Robertson
MZMichele Zagnoni
Michele Zagnoni
TBTrevor Bushell
Trevor Bushell
New in vitro technologies that assess neuronal excitability and the derived synaptic activity within a controlled microenvironment would be beneficial for the characterisation of compounds proposed to affect central nervous system (CNS) function. Here, a microfluidic system with computer controlled compound perfusion is presented that offers a novel methodology for the pharmacological profiling of CNS acting compounds based on calcium imaging readouts. Using this system, multiple applications of the excitatory amino acid glutamate (10 nM–1 mM) elicited reproducible and reversible transient increases in intracellular calcium, allowing the generation of a concentration response curve. In addition, the system allows pharmacological investigations to be performed as evidenced by application of glutamatergic receptor antagonists, reversibly inhibiting glutamate-induced increases in intracellular calcium. Importantly, repeated glutamate applications elicited significant increases in the synaptically driven activation of the adjacent, environmentally isolated neuronal network. Therefore, the proposed new methodology will enable neuropharmacological analysis of CNS active compounds whilst simultaneously determining their effect on synaptic connectivity.